News
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
IMV Inc. (the “Company” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) today announced that on April 29, 2023
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Abivax postpones the publication of its 2023 Universal Registration Document
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: Formycon publishes results for financial year 2022
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Evolva publishes timeline of the Reverse Stock Split
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc